BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/26/2016 8:04:00 AM | Browse: 1203 | Download: 2164
 |
Received |
|
2016-05-12 09:11 |
|
Peer-Review Started |
|
2016-05-13 08:27 |
|
To Make the First Decision |
|
2016-06-20 09:03 |
|
Return for Revision |
|
2016-06-20 16:07 |
|
Revised |
|
2016-07-24 07:54 |
|
Second Decision |
|
2016-08-17 13:42 |
|
Accepted by Journal Editor-in-Chief |
|
2016-08-17 14:38 |
|
Accepted by Company Editor-in-Chief |
|
2016-08-23 17:02 |
|
Articles in Press |
|
2016-08-23 17:02 |
 |
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2016-09-22 15:47 |
|
Publish the Manuscript Online |
|
2016-09-26 08:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Greg Rosenfeld, Astrid-Jane Greenup, Andrew Round, Oliver Takach, Lawrence Halparin, Abid Saadeddin, Jin Kee Ho, Terry Lee, Robert Enns and Brian Bressler |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Greg Rosenfeld, MD, MHSc, FRCPC, CCFP, Clinical Assistant Professor, Department of Medicine, Division of Gastroenterology, St. Paul’s Hospital, University of British Columbia, 770 - 1190 Hornby Street, Vancouver, BC V6Z 2K5, Canada. greg.rosenfeld@me.com |
| Key Words |
Inflammatory bowel disease; Biomarkers; Fecal calprotectin; Colonoscopy; Physician perspective |
| Core Tip |
Fecal calprotectin (FC) is a biomarker that provides a method of non-invasive assessment for intestinal inflammation. We evaluated the perspective of a group of gastroenterologists regarding the clinical use of FC, in particular the impact it has on the management of patients with inflammatory bowel disease (IBD). Patients with suspected or known IBD were recruited for study participation. A “pre survey” and “post survey” were completed by the physician prior to and after receipt of the FC result respectively. Of the 279 FC and surveys completed, FC levels resulted in a change in management 51.3% of the time and resulted in a significant reduction in colonoscopies performed. |
| Publish Date |
2016-09-26 08:04 |
| Citation |
Rosenfeld G, Greenup AJ, Round A, Takach O, Halparin L, Saadeddin A, Ho JK, Lee T, Enns R, Bressler B. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease. World J Gastroenterol 2016; 22(36): 8211-8218 |
| URL |
http://www.wjgnet.com/1007-9327/full/v22/i36/8211.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v22.i36.8211 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
